About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/17/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/17/2021.

EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY

Clinicaltrials.gov identifier NCT03932474

Recruitment Status Completed

First Posted April 30, 2019

Last update posted May 2, 2019

Study Description

Brief summary:

This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision) diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale.

  • Condition or Disease:Depressive Symptoms
  • Intervention/Treatment: Combination Product: SAMEUp
    Other: Placebo
  • Phase: N/A
Detailed Description

Depression is a common condition of low mood and aversion to activity that can affect a person's thoughts, behaviour, tendencies, feelings, and sense of well-being. Several literature findings suggest that an oral combination of the two food supplements SAMe (S-adenosyl-L-methionine) and probiotic Lactobacillus plantarum might be favourable in relieving some of symptoms of depression, particularly in the mild to moderate forms of this condition. This double blind placebo controlled clinical study aims to evaluate this hypothesis. In particular, the primary objective is to assess, versus placebo, the efficacy of SAMEUp in improving the overall symptomology of depression after 6 weeks of treatment. Subjects with mild to moderate depression were identified according to ICD-10 diagnostic criteria and confirmed by mean of Zung's Self-Rating Depression Scale. SAMEUp, the investigational food supplement, is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU, already notified to the Ministry of Health as food supplement. Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are indistinguishable.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 90 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment
  • Official Title: DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY OF SAMEUP IN SUBJECTS CHARACTERIZED BY MILD TO MODERATE DEPRESSION SYMPTOMS
  • Actual Study Start Date: September 2018
  • Actual Primary Completion Date: November 2018
  • Actual Study Completion Date: November 2018
Arms and interventions
Arm Intervention/treatment
Experimental: SAMEUp
SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
Combination Product: SAMEUp
One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
Placebo Comparator: Placebo
Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
Other: Placebo
One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
Outcome Measures
  • Primary Outcome Measures: 1. Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Depression Scale
  • Secondary Outcome Measures: 1. Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the total score of the Zung's Self-Rating Depression Scale
  • 2. Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the core depressive factor of the Zung's Self-Rating Depression Scale.
  • 3. Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the core depressive factor of the Zung's Self-Rating Depression Scale.
  • 4. Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the cognitive factor of the Zung's Self-Rating Depression Scale.
  • 5. Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the cognitive factor of the Zung's Self-Rating Depression Scale.
  • 6. Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the anxiety factor of the Zung's Self-Rating Depression Scale.
  • 7. Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the anxiety factor of the Zung's Self-Rating Depression Scale.
  • 8. Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the somatic factor of the Zung's Self-Rating Depression Scale.
  • 9. Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the somatic factor of the Zung's Self-Rating Depression Scale.
  • 10. Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the total score of the Zung's Self-Rating Anxiety Scale.
  • 11. Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the total score of the Zung's Self-Rating Anxiety Scale.
  • 12. Improvement in the insomnia condition evaluated through the Insomnia Severity Index [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the total score of the Insomnia Severity Index.
  • 13. Improvement in the insomnia condition evaluated through the Insomnia Severity Index [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the total score of the Insomnia Severity Index.
  • 14. Improvement in IBS (Irritable Bowel Syndrome) symptoms evaluated through the IBS questionnaire [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the total score of the IBS questionnaire.
  • 15. Improvement in IBS symptoms evaluated through the IBS questionnaire [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the total score of the IBS questionnaire.
  • 16. Improvement in the overall health status as measured by the EQ-5D-3L questionnaire [ Time Frame: 2 weeks ]
    Absolute change from baseline to two treatment-week of the EQ-5D-3L questionnaire.
  • 17. Improvement in the overall health status as measured by the EQ-5D-3L questionnaire [ Time Frame: 6 weeks ]
    Absolute change from baseline to six treatment-week of the EQ-5D-3L questionnaire.
  • 18. Evaluation of the patient's satisfaction grade [ Time Frame: 6 weeks ]
    Subject's satisfaction grade at the end of the treatment.
  • 19. Incidence of adverse events described as per frequency and relationship with the study product [ Time Frame: 6 weeks ]
    Adverse events occurrence during the study
Eligibility Criteria
  • Ages Eligible for Study: 18 to 60 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Written informed consent, personally signed and dated by the subject.

2. Males and females, aging 18-60 years old (limits included).

3. Diagnosis of mild to moderate recurrent depressive disorder according to the ICD-10 /
F33 criteria (World Health Organization, 2004).

4. Subject who, having completed the Z-SDS depression questionnaire, has a raw score
between 41 and 55 (including limits).

5. Subject able to comprehend the full nature and purpose of the study, available to
cooperate with the Investigator and to comply with the requirements of the entire
study.

Exclusion Criteria:

1. Pregnant or breast-feeding woman.

2. Subject with one or more psychiatric disturbances, such as: alcoholism, substance
abuse or dependency disorder, bipolar disorder, schizophrenia, or other personality
disorder.

3. Subject with known or potential hypersensitivity to any ingredient in the study
product.

4. Subject in treatment with psycholeptic drug, such as: antipsychotics, anxiolytics,
hypnotics and sedatives.

5. Subject who has taken during the 2 weeks prior to inclusion, who is currently taking
or plans to take other orally administered food supplements except the study product.
Only multivitamins, salts and trace elements are accepted

Contacts and Locations
Contacts
Locations

Italy
Hippocrates Research
Genoa

Sponsors and Collaborators

Nutrilinea srl

Hippocrates Research

More Information
  • Responsible Party: Nutrilinea srl
  • ClinicalTrials.gov Identifier: NCT03932474 History of Changes
  • Other Study ID Numbers: SAMEUP
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: May 2, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Nutrilinea srl: depression
    probiotic
    SAMe
    Lactobacillus plantarum 299v
    anxiety
    insomnia
    irritable bowel syndrome
    randomized controlled study
  • Additional relevant MeSH terms: Depression